BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Executive Summary

• BriaCell Therapeutics closed its best‑efforts public offering of 5,366,726 units at US$5.59 per unit, generating approximately US$30 million in gross proceeds.
• Each unit comprised one common share (or pre‑funded warrant) and one warrant exercisable at US$6.93 per share, with the warrants listed on Nasdaq Capital Market under “BCTXL” on Jan 14 2026.
• Net proceeds are earmarked for working capital, general corporate purposes, and advancing the company’s immunotherapy programs.

Key Details

• Offering Size: 5,366,726 units sold to the public.
• Pricing: US$5.59 per unit (inclusive of pre‑funded warrant exercise price).
• Gross Proceeds: Approximately US$30 million before placement agent fees and offering expenses.
• Unit Composition: One common share (or one pre‑funded warrant) + one warrant.
• Warrant Terms: Immediately exercisable; purchase one common share at US$6.93; expires five years from issuance.
• Listing: Warrants listed on Nasdaq Capital Market, trading under ticker “BCTXL” as of Jan 14 2026.
• Placement Agent: ThinkEquity acted as sole placement agent.
• Regulatory Filings: Form S‑1 (File No. 333-292388) filed Dec 23 2025; became effective Jan 13 2026. Additional registration under Rule 462(b) filed Jan 13 2026. Prospectus available via ThinkEquity and SEC website.
• Use of Proceeds: Funding working capital, general corporate purposes, and further development of BriaCell’s immunotherapy pipeline.
• Exemption Relied Upon: Section 602.1 of the TSX Company Manual for inter‑listed issuer transactions.

Notable Quotes

(No executive quotes were included in the release.)